Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

• Main Authors: Michael J. Cork (Author), Benjamin Lockshin (Author), Andreas Pinter (Author), Zhen Chen (Author), Brad Shumel (Author), Randy Prescilla (Author)
• Format: Book
• Published: Medical Journals Sweden, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moder...